DeepHealth boosts ultrasound AI by integrating See-Mode team
DeepHealth will incorporate See-Mode Technologies' expertise and AI technologies for thyroid and breast ultrasound into its population health solutions following RadNet's acquisition of See-Mode Technologies.
See-Mode's commercially available AI-powered ultrasound detection, characterisation, and reporting solutions for thyroid and breast will be added to DeepHealth's suite of services. These technologies automatically detect and characterise thyroid nodules and breast lesions during ultrasound imaging, aiming to improve diagnostic accuracy and streamline clinical workflows through the generation of standardised reports.
The integration is set against the backdrop of rising global rates of thyroid cancer, which is among the fastest-growing cancer diagnoses worldwide. Alongside breast cancer, it remains a prevalent pathology, particularly impacting women.
Real-world deployment of See-Mode's FDA-cleared thyroid ultrasound AI at selected RadNet imaging centres has already shown operational benefits, with workflow efficiency improvements and enhancements to diagnostic accuracy. The company reported that the inclusion of See-Mode's automated detection and reporting has resulted in up to a 30 per cent reduction in scan time in the centres where it has been piloted.
Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, "Thyroid cancer is one of the fastest growing cancer diagnoses worldwide and, alongside breast cancer, is among the most common cancers affecting women. In the US alone, approximately 20 million ultrasound exams are performed annually for thyroid and breast combined. With ultrasound imaging inherently complex and user and radiologist-dependent, the opportunity to improve care through AI is significant."
Dr. Berger further noted, "Early deployment of See-Mode's FDA-approved thyroid ultrasound AI across a portion of our imaging centers has demonstrated up to a 30% reduction in scan time as a result of increased workflow efficiency from See-Mode's automated detection and reporting. With demand exceeding available appointment slots for many of our over 900 ultrasound units, the increase in capacity created by See-Mode's technology should improve our ability to drive better access and more revenue through RadNet's existing centers. Furthermore, there is already a reimbursement code that makes a portion of our approximately 250,000 annual thyroid ultrasounds eligible for additional reimbursement. We aim to expand these efficiencies to breast screening and other clinical areas in our more than two million annual ultrasound studies. These opportunities will also be sold and marketed by DeepHealth to third parties as we further commercialize the offerings."
See-Mode's AI technologies are currently cleared for commercial distribution in the United States, Canada, Australia, New Zealand, and Singapore. The acquisition supports DeepHealth's stated objective to strengthen its portfolio of AI-driven population health solutions and to address clinical and operational challenges in high-volume care settings.
Dr. Milad Mohammadzadeh, Co-Founder of See-Mode, added: "Ultrasound is complex, time-consuming, and high-volume—exactly where AI can make a difference. By joining RadNet and DeepHealth's combined access to real-world clinical data and expertise at an unprecedented scale, we have an extraordinary platform to build the future of ultrasound."
Echoing these remarks, Kees Wesdorp, President and Chief Executive Officer of RadNet's Digital Health division, said: "We are excited to integrate See-Mode's technology in thyroid and breast ultrasound into DeepHealth's comprehensive portfolio of AI-powered solutions for breast, lung, prostate, and brain, to address clinical and operational challenges in high-volume care settings. The technology and the team's expertise will be the basis for future AI-powered ultrasound solutions that will add to the growth engine of DeepHealth."
According to the information provided, DeepHealth currently operates more than 900 ultrasound units, conducting over two million ultrasound examinations each year. The company expects that the integration of See-Mode's technology will allow it to manage greater demand, improve workflow efficiencies, and address current appointment slot limitations.
Industry sources cited in the release note that in the United States alone, approximately 20 million ultrasound exams are performed each year for thyroid and breast combined. RadNet and DeepHealth aim to capitalise on these volumes by promoting their expanded suite of AI-driven solutions to both internal and third-party customers.
See-Mode's team and technology base in Singapore and Australia will join the DeepHealth operations, contributing their expertise to ongoing and future development of AI-driven ultrasound solutions. This collaboration is expected to facilitate the development of new applications in high-volume diagnostic imaging and to support improved access and outcomes across RadNet's network of imaging centres.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Techday NZ
2 days ago
- Techday NZ
DeepHealth boosts ultrasound AI by integrating See-Mode team
DeepHealth will incorporate See-Mode Technologies' expertise and AI technologies for thyroid and breast ultrasound into its population health solutions following RadNet's acquisition of See-Mode Technologies. See-Mode's commercially available AI-powered ultrasound detection, characterisation, and reporting solutions for thyroid and breast will be added to DeepHealth's suite of services. These technologies automatically detect and characterise thyroid nodules and breast lesions during ultrasound imaging, aiming to improve diagnostic accuracy and streamline clinical workflows through the generation of standardised reports. The integration is set against the backdrop of rising global rates of thyroid cancer, which is among the fastest-growing cancer diagnoses worldwide. Alongside breast cancer, it remains a prevalent pathology, particularly impacting women. Real-world deployment of See-Mode's FDA-cleared thyroid ultrasound AI at selected RadNet imaging centres has already shown operational benefits, with workflow efficiency improvements and enhancements to diagnostic accuracy. The company reported that the inclusion of See-Mode's automated detection and reporting has resulted in up to a 30 per cent reduction in scan time in the centres where it has been piloted. Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, "Thyroid cancer is one of the fastest growing cancer diagnoses worldwide and, alongside breast cancer, is among the most common cancers affecting women. In the US alone, approximately 20 million ultrasound exams are performed annually for thyroid and breast combined. With ultrasound imaging inherently complex and user and radiologist-dependent, the opportunity to improve care through AI is significant." Dr. Berger further noted, "Early deployment of See-Mode's FDA-approved thyroid ultrasound AI across a portion of our imaging centers has demonstrated up to a 30% reduction in scan time as a result of increased workflow efficiency from See-Mode's automated detection and reporting. With demand exceeding available appointment slots for many of our over 900 ultrasound units, the increase in capacity created by See-Mode's technology should improve our ability to drive better access and more revenue through RadNet's existing centers. Furthermore, there is already a reimbursement code that makes a portion of our approximately 250,000 annual thyroid ultrasounds eligible for additional reimbursement. We aim to expand these efficiencies to breast screening and other clinical areas in our more than two million annual ultrasound studies. These opportunities will also be sold and marketed by DeepHealth to third parties as we further commercialize the offerings." See-Mode's AI technologies are currently cleared for commercial distribution in the United States, Canada, Australia, New Zealand, and Singapore. The acquisition supports DeepHealth's stated objective to strengthen its portfolio of AI-driven population health solutions and to address clinical and operational challenges in high-volume care settings. Dr. Milad Mohammadzadeh, Co-Founder of See-Mode, added: "Ultrasound is complex, time-consuming, and high-volume—exactly where AI can make a difference. By joining RadNet and DeepHealth's combined access to real-world clinical data and expertise at an unprecedented scale, we have an extraordinary platform to build the future of ultrasound." Echoing these remarks, Kees Wesdorp, President and Chief Executive Officer of RadNet's Digital Health division, said: "We are excited to integrate See-Mode's technology in thyroid and breast ultrasound into DeepHealth's comprehensive portfolio of AI-powered solutions for breast, lung, prostate, and brain, to address clinical and operational challenges in high-volume care settings. The technology and the team's expertise will be the basis for future AI-powered ultrasound solutions that will add to the growth engine of DeepHealth." According to the information provided, DeepHealth currently operates more than 900 ultrasound units, conducting over two million ultrasound examinations each year. The company expects that the integration of See-Mode's technology will allow it to manage greater demand, improve workflow efficiencies, and address current appointment slot limitations. Industry sources cited in the release note that in the United States alone, approximately 20 million ultrasound exams are performed each year for thyroid and breast combined. RadNet and DeepHealth aim to capitalise on these volumes by promoting their expanded suite of AI-driven solutions to both internal and third-party customers. See-Mode's team and technology base in Singapore and Australia will join the DeepHealth operations, contributing their expertise to ongoing and future development of AI-driven ultrasound solutions. This collaboration is expected to facilitate the development of new applications in high-volume diagnostic imaging and to support improved access and outcomes across RadNet's network of imaging centres.
Otago Daily Times
28-05-2025
- Otago Daily Times
US drops Covid jab recommendation for healthy kids, pregnant women
The US has stopped recommending routine Covid-19 vaccinations for pregnant women and healthy children, Health Secretary Robert F. Kennedy Jr announced in a social media post, circumventing the CDC's traditional recommendation process. Kennedy, FDA commissioner Marty Makary and National Institutes of Health director Jay Bhattacharya said in a video that the shots had been removed from the Centers for Disease Control and Prevention's recommended immunization schedule. The changes come a week after they unveiled tighter requirements for Covid shots, effectively limiting them to older adults and those at risk of developing severe illness. Traditionally, the CDC's Advisory Committee for Immunization Practices would meet and vote on changes to the immunization schedule or recommendations on who should get vaccines before the director of the CDC made a final call. The committee has not voted on these changes. Kennedy, a long-time vaccine skeptic whose department oversees the CDC, has been remaking the US health system to align with President Donald Trump's goal of dramatically shrinking the federal government. "Last year, the Biden Administration urged healthy children to get yet another Covid shot despite the lack of clinical data to support repeat booster strategy in children," Kennedy said in the video. The CDC, following its panel of outside experts, previously recommended updated Covid vaccines for everyone aged six months and older. Insurers said they are reviewing the regulatory guidance to determine their policies, which typically follow the ACIP recommendations. A spokesperson for CVS Health CVS.N said the company was determining whether changes in health insurance coverage were required as the federal government reassessed Covid-19 vaccine eligibility, while a Blue Cross Blue Shield Association spokesperson said preventative health benefits, including Covid vaccines, were essential in keeping patients healthy. 'TURNED UPSIDE DOWN' "The recommendation is coming down from the secretary, so the process has just been turned upside down," said William Schaffner, professor of infectious diseases at Vanderbilt University Medical Center and a consultant to the ACIP. Schaffner said the CDC's panel was to vote on these issues at a June meeting, where he had expected them to favour more targeted shots instead of a universal vaccine recommendation. "But this seems to be a bit preemptory," he said. Dorit Reiss, professor of law at UC Law San Francisco, said in a Facebook post that going around the advisory committee might hurt the agency in the case of potential litigation. Studies with hundreds of thousands of people around the world show that Covid-19 vaccination before and during pregnancy is safe, effective, and beneficial to both the pregnant woman and the baby, according to the CDC's website. But Makary said in the video that there was no evidence that healthy children needed routine Covid shots. Most countries had stopped recommending them for children, he added. Covid vaccine makers Moderna and Pfizer did not respond to requests for comment. Dr Cody Meissner, professor of pediatrics at Dartmouth who co-wrote an editorial with Makary during the Covid pandemic against masks for children, said he agreed with the decision. He said he felt the US had been overemphasizing the importance of the Covid vaccine for young children and pregnant women, and that previous recommendations were based on politics, adding that the severity of the illness generated by the virus seemed to have lessened over time in young children.
RNZ News
27-05-2025
- RNZ News
US will no longer recommend COVID-19 vaccine to children or healthy pregnant women
By ABC/AFP Health Secretary Robert F Kennedy Jr. Photo: ALEX WONG / AFP The US will no longer recommend COVID-19 vaccines for children and healthy pregnant women, with Health Secretary Robert F Kennedy Jr calling it a "common sense" decision grounded in sound science . The change follows last week's announcement by Food and Drug Administration (FDA) officials that they would limit approval of COVID-19 shots, a critical tool in ending the pandemic, to adults aged 65 and older, as well as younger individuals with underlying health conditions. Trump administration officials have framed the shift as bringing the US into closer alignment with countries like Britain, Germany and France, where annual boosters are recommended only for the elderly and immunocompromised. But it comes as Kennedy, who has long promoted misinformation about vaccines in general and the COVID-19 shots in particular, pushes to overhaul federal public health policy. "I couldn't be more pleased to announce that as of today, the COVID vaccine for healthy children and healthy pregnant women has been removed from the CDC [Centres for Disease Control and Prevention] recommended immunisation schedule," he said in a video posted to X. FDA officials also said vaccine manufacturers would need to conduct new clinical trials, including comparisons against a saline placebo, if they wished to retain approval for use in healthy people under 65. These recent changes have drawn criticism. Infectious diseases specialist at Johns Hopkins University Amesh Adalja told news agency AFP last week that while the new approach matched that taken by other countries, "I do think, however, that the initial COVID-19 vaccine series should be part of routine childhood immunisation". Top vaccine expert at the Children's Hospital of Philadelphia Paul Offit warned the change could restrict access for people who still wanted boosters, particularly under the US's privatised healthcare system, where insurers might decline coverage. The reversal on pregnant women marks a major departure from previous CDC guidance. As of Tuesday morning, the agency's website, which had yet to reflect Kennedy's announcement, still stated that pregnant women were among people for whom it was "especially important" to receive the vaccine. "If you are pregnant or were recently pregnant, you are more likely to get very sick from COVID-19 compared to those who are not pregnant," it said. - ABC/AFP
